Regeneron News and Research

RSS
Bayer, Regeneron commence EYLEA Phase 3 clinical trial for wet AMD in China

Bayer, Regeneron commence EYLEA Phase 3 clinical trial for wet AMD in China

FDA accepts Regeneron's ARCALYST sBLA for review

FDA accepts Regeneron's ARCALYST sBLA for review

Regeneron’s Eylea for treating age related macular degeneration gets FDA nod

Regeneron’s Eylea for treating age related macular degeneration gets FDA nod

FDA approves EYLEA for treatment of wet Age-related Macular Degeneration

FDA approves EYLEA for treatment of wet Age-related Macular Degeneration

Regeneron receives FDA approval for Eylea to treat wet AMD

Regeneron receives FDA approval for Eylea to treat wet AMD

Combination of REGN910 and aflibercept inhibits tumor angiogenesis in animal models

Combination of REGN910 and aflibercept inhibits tumor angiogenesis in animal models

Regeneron announces positive results from sarilumab Phase 2b trial on RA

Regeneron announces positive results from sarilumab Phase 2b trial on RA

Regeneron announces additional data from aflibercept Phase 3 trial on colorectal cancer

Regeneron announces additional data from aflibercept Phase 3 trial on colorectal cancer

Positive results from sarilumab Phase 2b trial on RA, ankylosing spondylitis

Positive results from sarilumab Phase 2b trial on RA, ankylosing spondylitis

Bayer Yakuhin seeks marketing authorization in Japan for EYLEA for treatment of wet AMD

Bayer Yakuhin seeks marketing authorization in Japan for EYLEA for treatment of wet AMD

NASDAQ halts Regeneron's common stock

NASDAQ halts Regeneron's common stock

Bayer HealthCare seeks EU marketing authorization of VEGF Trap-Eye for treatment of wet AMD

Bayer HealthCare seeks EU marketing authorization of VEGF Trap-Eye for treatment of wet AMD

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

FDA accepts Regeneron's VEGF Trap-Eye BLA for review

FDA accepts Regeneron's VEGF Trap-Eye BLA for review

Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema

Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema

Sanofi-aventis, Regeneron announce results of VEGF Trap Phase III trial in second-line NSCLC

Sanofi-aventis, Regeneron announce results of VEGF Trap Phase III trial in second-line NSCLC

EHSI to sign definitive agreement with OceanBASIS

EHSI to sign definitive agreement with OceanBASIS

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

Regeneron, Bayer and SERI initiate new VEGF Trap-Eye Phase 3 clinical trial in myopic CNV

Regeneron, Bayer and SERI initiate new VEGF Trap-Eye Phase 3 clinical trial in myopic CNV